Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|March 29, 2005
Objective assessment of the perineural vascular plexus as a landmark for the horizontal part of the facial nerve in middle ear and mastoid surgeryVinidh Paleri, Carl WatsonOtology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|September 17, 2014
Recurrence rate of cholesteatoma with autoclaved incus autograftWoo-Young Yang, Carl WatsonThe AAPS Journal|February 7, 2014
Recommendations and best practices for reference standards and reagents used in bioanalytical method validationJoseph F Bower, Jennifer B McClung, Carl Watson, et al.Molecular Ecology|August 18, 2025
Arid Soil Bacterial Legacies Improve Drought Resilience of the Keystone Grass, Themeda triandraRiley J Hodgson, Christian Cando-Dumancela, Tarryn Davies, et al.Journal for Immunotherapy of Cancer|January 16, 2026
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumorsIgnacio Melero, Neeltje Steeghs, Ulrik Lassen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid TumorsNeeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, et al.Science Translational Medicine|June 17, 2021
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan depositionStefan Bissinger, Carina Hage, Vinona Wagner, et al.European Journal of Cancer (Oxford, England : 1990)|November 8, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid TumorsSolange Peters, Eric Angevin, Teresa Alonso-Gordoa, et al.Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.Pageof 2